β-Blocker dosing in community-based treatment of heart failure

Philbin, 1999, Clinical outcomes in heart failure: report from a community hospital–based registry, Am J Med, 107, 549, 10.1016/S0002-9343(99)00309-5 Chin, 1997, Differences in generalist and specialist physicians' knowledge and use of angiotensin-converting enzyme inhibitors for congestive heart failure, J Gen Intern Med, 12, 523, 10.1046/j.1525-1497.1997.07105.x Edep, 1997, Differences between primary care physicians and cardiologists in management of congestive heart failure: relation to practice guidelines, J Am Coll Cardiol, 30, 518, 10.1016/S0735-1097(97)00176-9 Franciosa, 2004, Beta-blocker therapy for heart failure outside the clinical trial setting: findings of a community-based registry, Am Heart J, 148, 718, 10.1016/j.ahj.2004.04.006 Franciosa, 2004, The potential role of community-based registries to complement the limited applicability of clinical trial results to the community setting: heart failure as an example, Am J Manag Care, 10, 487 Stafford, 2003, The underutilization of cardiac medications of proven benefit, 1990 to 2002, J Am Coll Cardiol, 41, 56, 10.1016/S0735-1097(02)02670-0 Gupta, 2004, Patterns of beta-blocker utilization in patients with chronic heart failure: experience from a specialized outpatient heart failure clinic, Am Heart J, 147, 79, 10.1016/j.ahj.2003.07.022 Maggioni, 2003, Treatment of chronic heart failure with beta adrenergic blockade beyond controlled clinical trials: the BRING-UP experience, Heart, 89, 299, 10.1136/heart.89.3.299 Mehta, 2004, Heart failure in a district general hospital: are target doses of beta-blockers realistic?, Q J Med, 97, 133, 10.1093/qjmed/hch023 Young, 2002, Few CHF patients achieve target dosages of beta blockers, risking hospitalizations and death, Formulary, 37, 321 Packer, 1996, The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group, N Engl J Med, 334, 1349, 10.1056/NEJM199605233342101 CIBIS-II Investigators and Committees, 1999, The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial, Lancet, 353, 9, 10.1016/S0140-6736(98)11181-9 1999, Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF), Lancet, 353, 2001, 10.1016/S0140-6736(99)04440-2 Brophy, 2001, Beta-blockers in congestive heart failure. A Bayesian meta-analysis, Ann Intern Med, 134, 550, 10.7326/0003-4819-134-7-200104030-00008 Bristow, 1996, Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure, Circulation, 94, 2807, 10.1161/01.CIR.94.11.2807 Krum, 2003, Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study, JAMA, 289, 712, 10.1001/jama.289.6.712 Wikstrand, 2002, Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF), J Am Coll Cardiol, 40, 491, 10.1016/S0735-1097(02)01970-8 Simon, 2003, Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study (CIBIS II), Eur Heart. J, 24, 552, 10.1016/S0195-668X(02)00743-1 Franciosa, 2000, Rationale, design, and methods for a Coreg (Carvedilol) Heart Failure Registry (COHERE), J Cardiac Fail, 6, 264, 10.1054/jcaf.2000.9675 Poole-Wilson, 2003, Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomized controlled trial, Lancet, 362, 7, 10.1016/S0140-6736(03)13800-7 Rutten, 2003, Differences between general practitioners and cardiologists in diagnosis and management of heart failure: a survey in every-day practice, Eur J Heart Fail, 5, 337, 10.1016/S1388-9842(03)00050-3 Philbin, 1996, Patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure in two community hospitals, Am J Cardiol, 77, 832, 10.1016/S0002-9149(97)89177-1 Fowler, 2001, Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. U.S. Carvedilol Heart Failure Study Group, J Am Coll Cardiol, 37, 1692, 10.1016/S0735-1097(01)01190-1 Packer, 1999, Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and morality in chronic heart failure. ATLAS Study Group, Circulation, 100, 2312, 10.1161/01.CIR.100.23.2312 Massie BM, Nelson JJ, Lukas MA, et al, and the COHERE Participant Physicians. Comparison of outcomes and usefulness of carvedilol across a spectrum of left ventricular ejection fractions in heart failure patients in clinical practice. Am J Cardiol [in press].